尼妥珠单抗联合mFOLFOX6方案治疗晚期转移性结肠癌的效果观察  

Effect of Nimotuzumab combined with mFOLFOX6 in treating advanced metastatic colon cancer

作　　者：李永亮 彭荣荣 代丽雯 Li Yong-liang;Peng Rong-rong;Dai Li-wen(Department of Pharmacy,Xinyang Central Hospital,Xinyang 464000,Henan,China)

机构地区：[1]信阳市中心医院药学科,河南信阳464000

出　　处：《四川生理科学杂志》2025年第4期855-858,共4页

摘　　要：目的:分析尼妥珠单抗联合氟尿嘧啶、奥沙利铂、亚叶酸钙(mFOLFOX6)方案治疗晚期转移性结肠癌(Metastatic colorectal cancer,mCRC)的临床效果。方法:回顾性收集2021.5~2023.5期间于本院治疗的89例mCRC患者的病历资料,根据治疗方案的不同分为研究组(n=46)和对照组(n=43),分别予以mFOLFOX6方案以及基于此方案增加尼妥珠单抗(第1 d予以200 mg静脉滴注1 h,每w 1次,连续治疗8 w)。统计两组患者治疗8 w后疗效及治疗期间毒副反应,并统计无进展生存期,治疗前与治疗8 w后使用电化学发光分析仪检测血清甲胎蛋白(Alpha fetoprotein,AFP)、糖类抗原72-4(Carbohydrate antigen72-4,CA72-4)、糖类抗原199(Carbohydrate antigen199,CA199)、糖类抗原125(Carbohydrate antigen 125,CA125)水平,经酶联免疫吸附法检测血清趋化因子配体5(Chemokine receptor 5,CXCL5)、CXCL21、胸苷激酶1(Thymidine kinase 1,TK1)水平。结果:研究组的客观有效率显著高于对照组(P<0.05)。两组的毒副反应无显著差异(P>0.05)。治疗8 w后,两组的AFP、CA72-4、CA199、CA125均比治疗前显著下降,且研究组的AFP、CA72-4、CA199、CA125均显著低于对照组(P<0.05)。治疗8 w后,两组的CXCL5、CXCL21、TK1均显著低于治疗前,且研究组的CXCL5、CXCL21、TK1均显著低于对照组(P<0.05)。研究组中位无进展生存期显著高于对照组(P<0.05)。结论:尼妥珠单抗联合mFOLFOX6方案治疗mCRC,可增强抗肿瘤效果,提高客观有效率,延长无进展生存期。Objective:To analyze the clinical efficacy of the combination of nimotuzumab with modified fluorouracil,oxaliplatin,and calcium folinate(mFOLFOX6)regimen in treating advanced metastatic colorectal cancer(mCRC).Methods:The medical records of 89 patients with mCRC treated in our hospital between 2021.5 and 2023.5 were retrospectively collected and divided into a study group(n=46)and a control group(n=43)according to the treatment regimen.mFOLFOX6 regimen and the addition of nituzumab based on the regimen(200 mg intravenously for 1 hours on the first day,once every week)were administered,respectively,and the patients in both groups were counted after 8 weeks of treatment.The efficacy of the two groups of patients after 8 weeks of treatment and toxic side effects during the treatment period,as well as progression-free survival,before and after 8 w of treatment,serum Alpha feto protein(AFP),Carbohydrate antigen72-4(CA72-4),Carbohydrate antigen199(CA199)and Carbohydrate antigen 125(CA125)levels were detected by the electrochemiluminescence analyzer,and serum chemokine levels were detected by enzyme-linked immunosorbent assay(ELISA).Serum levels of Chemokine receptor 5(CXCL5),CXCL21 and Thymidine kinase 1(TK1)were measured by enzyme-linked immunosorbent assay.Results:The objective efficiency rate in the study group was significantly higher than that in the control group(P<0.05).There was no significant difference in the toxic and side effects between the two groups(P>0.05).After 8 weeks of treatment,AFP,CA72-4,CA199,and CA125 in both groups were decreased significantly compared with those before treatment,and AFP,CA72-4,CA199,and CA125 in the study group were significantly lower than those in the control group(P<0.05).After 8 weeks of treatment,CXCL5,CXCL21,and TK1 in both groups were significantly lower than before treatment,and CXCL5,CXCL21,and TK1 in the study group were significantly lower than those in the control group(P<0.05).The median progression-free survival time in the study group was significantly higher th

关 键 词：尼妥珠单抗 结直肠癌 无进展生存期 毒副反应 

分 类 号：R735.3[医药卫生—肿瘤]